Market share in 2023 vs 2024: Ingrezza vs. Austedo (what’s publicly knowable)
Public market-share figures for specific brands like Ingrezza (valbenazine) and Austedo (deutetrabenazine) are not consistently published in one place on a year-by-year basis, and what’s available often comes from paid sales tracking (e.g., IQVIA/Nielsen) or from company-reported trends rather than a single authoritative “market share” chart.
What can be pinned down from the public record is how each drug’s commercial position moved across that period—mainly through reported revenue trends, prescription growth/declines, and competitive uptake—rather than a universally cited percentage market share for both products in 2023 and 2024.
If you mean “treatment share” in tardive dyskinesia (TD)
Ingrezza is the better-known brand specifically tied to tardive dyskinesia. Austedo is also used in movement-disorder indications, including TD in some settings. In practice, the “share” question for TD often ends up being about:
- how much of the TD-prescribing pool goes to Ingrezza versus deutetrabenazine (Austedo),
- whether one product’s uptake is driven more by payer coverage, neurologist prescribing patterns, or patient switching.
To answer with hard percentages for 2023 and 2024, you generally need brand-sales share data from IQVIA or similar sources, which aren’t included in the information provided here.
If you mean “revenue share” of each brand’s market category
A related way people estimate market share is by comparing each brand’s sales to the total sales of competing therapies in the same category/indication. Again, those totals are usually derived from commercial sales datasets rather than a freely accessible public table.
The most actionable next step (so you get the exact 2023/2024 percentages)
Tell me which definition you want:
1) “Market share” for tardive dyskinesia prescriptions (Ingrezza vs Austedo only), or
2) “Market share” based on brand sales in the broader VMAT2 inhibitor / movement-disorder category, or
3) “Market share” including other comparators in TD besides these two.
Also share the geography (US only vs. US+EU) and whether you want:
- % share of prescriptions, or
- % share of dollars/revenue.
With that, I can format the result as “2023 vs 2024: Ingrezza share vs Austedo share” using the most relevant data source type available.
Patent/strategy context that can affect uptake (why share may shift between 2023 and 2024)
Competition between brands can shift because of exclusivity/patent posture, generics/biosimilar threats (where relevant), and payer contracting. If you want, I can also summarize the patent landscape relevant to Ingrezza and Austedo using DrugPatentWatch.com.
Source: DrugPatentWatch.com (patent/exclusivity tracking) [1]
Sources
- DrugPatentWatch.com